This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Canine Dilated Cardiomyopathy Drugs Market

Canine Dilated Cardiomyopathy Drugs Market By Drug Class (ACE Inhibitors, Vasodilators, Diuretics, Angiotensin II Receptor Blockers {ARB}, Cardiac Glycosides, Anti-arrhythmic, Pimobenden), Route of Administration (Oral, Injectable), Distribution Channel (Institutional Sales, Retail Sales) & Region - Forecast 2022-2032

Market Insights on Canine Dilated Cardiomyopathy Drugs covering sales outlook, demand forecast & up-to-date key trends

Canine Dilated Cardiomyopathy Drugs Market Overview

Global Canine Dilated Cardiomyopathy Market demand is anticipated to be valued at US$ 3.4 Billion in 2022, forecast to grow at a CAGR of 4.93% to be valued at US$ 5.5 Billion from 2022 to 2032. The growth of the Canine Dilated Cardiomyopathy Market is attributed to its global utilization across the Healthcare industry.

Report Attribute

Details

Estimated Base Year Value (2021)

US$ 2.3 Billion

Expected Market Value (2022)

US$ 3.4 Billion

Anticipated Forecast Value (2032)

US$ 5.5 Billion

Projected Growth Rate (2022-2032)

4.93% CAGR

Canine dilated cardiomyopathy drugs are used to treat heart muscle diseases, which causes the heart to weaken and enlarge. This results in weaken contraction and poor pumping ability of the heart. The canine dilated cardiomyopathy is prevalent in certain breeds of dog and is observed to be rare in crossbreed dogs.

Canine dilated cardiomyopathy drugs are directed at enhancing systolic (pump) function of the heart, dilating the peripheral blood vessels to lower ventricular workload, controlling heart rate and cardiac arrhythmias. Canine dilated cardiomyopathy drugs treatment goals are achieved by the administration of cardiac medication which may be delivered through injections in an emergency situation or orally in stable animals.

Asia Pacific is considered to be a dominant region for the Canine Dilated Cardiomyopathy Market during the forecast period, owing to the increasing pet culture in the region.

The major factor that is expected to propel the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes rising health benefits for pet animals.

The factor that is expected to hinder the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes the high cost and side effects associated with products and treatments

Which are Some Prominent Drivers Spearheading Canine Dilated Cardiomyopathy Market Growth?

The major factor that is expected to accelerate the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes potential growth of the pet industry.

In addition, dogs are estimated to account for the largest share in the pet industry due to rising health benefits for pet animals, which in turn is expected to fuel the growth of the Canine Dilated Cardiomyopathy Market during the forecast period.

Furthermore, increasing prevalence of cardiac diseases, technological advancement in the diagnostic treatments, and more life expectancy of animals are some other factors that are expected to propel the growth of canine dilated cardiomyopathy drugs market during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Challenges Faced by the Canine Dilated Cardiomyopathy Industry?

The major factor that is expected to hamper the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes the high cost and side effects associated with products and treatments.

Additionally, lack of veterinary infrastructure, as well as poor transportation links in some regions are some other factors that are expected to hinder the market growth.

How is Asia Pacific region emerging as an Opportunistic Canine Dilated Cardiomyopathy Market?

Asia Pacific is the largest market for Canine Dilated Cardiomyopathy, owing to the high prevalence of disease conditions such as cancer and cardiovascular diseases in the region. Moreover, India and China are promising markets for the growth of dilated cardiomyopathy market due to increasing incidences of Cancer among patients.

In addition, increase in various therapy devices including implantable cardioverter-defibrillators (ICDs), biventricular pacemakers and heart pumps in the Asia Pacific region is expected to fuel the growth of the Canine Dilated Cardiomyopathy Market in the region. The Asia Pacific canine dilated cardiomyopathy market is expected to expand at a 3% CAGR during the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is North America Contributing to Growth of the Canine Dilated Cardiomyopathy Market?

According to Future Market Insights, North America is anticipated to witness growth at a lucrative rate over the forecast period, owing to the increasing pet culture in the region. This factor is expected to fuel the growth of the Canine Dilated Cardiomyopathy Market in the region.

Further, growing incidences of Cancer in the US is expected to accelerate the market growth in the region in the forthcoming years.

Market Competition

Some of the key participants present in the global Canine Dilated Cardiomyopathy Market include C.H. Boehringer Sohn AG & Co., KG, Merck & Co., Dechra Pharmaceuticals PLC, Zoetis Inc., Bayer AG, Orion, Elanco, and SAVA Vet, among others.

Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as C.H. Boehringer Sohn AG & Co., and KG, Merck & Co. account for a considerable market size, several regional level players are also operating across key growth regions, particularly in the Asia Pacific.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 4.93% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Product Type
  • Route of Administration
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • C.H. Boehringer Sohn AG & Co.
  • KG, Merck & Co.
  • Dechra Pharmaceuticals PLC, Zoetis Inc.
  • Bayer AG
  • Orion, Elanco
  • SAVA Vet

Customization

Available Upon Request

Key Segments Profiled in the Canine Dilated Cardiomyopathy Drugs Industry Survey

Drug Class:

  • Canine Dilated Cardiomyopathy ACE Inhibitors
  • Canine Dilated Cardiomyopathy Vasodilators
  • Canine Dilated Cardiomyopathy Diuretics
  • Canine Dilated Cardiomyopathy Angiotensin II Receptor Blockers (ARB)
  • Canine Dilated Cardiomyopathy Cardiac Glycosides
  • Anti-arrhythmic Canine Dilated Cardiomyopathy Drugs
  • Pimobenden Canine Dilated Cardiomyopathy Drugs

Route of Administration:

  • Oral Canine Dilated Cardiomyopathy Drugs
  • Injectable Canine Dilated Cardiomyopathy Drugs

Distribution Channel:

  • Institutional Sales
    • Veterinary Hospitals
    • Veterinary Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global Canine Dilated Cardiomyopathy Market to expand at a 4.93% value CAGR by 2032

Asia Pacific is expected to be the most opportunistic Canine Dilated Cardiomyopathy Market, expanding at a 3% CAGR

C.H. Boehringer Sohn AG & Co., KG, Merck & Co., Dechra Pharmaceuticals PLC, Zoetis Inc., Bayer AG, Orion, Elanco, and SAVA Vet, among others are some prominent Canine Dilated Cardiomyopathy Market players

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Bipolar Disorder Drugs and Treatment Market

Published : March 2022

Healthcare

Veterinary Pain Management Drugs Market

Published : December 2016

Healthcare

Systemic Lupus Erythematous SLE Drugs Market

Published : March 2022

Healthcare

General Anesthesia Drugs Market

Published : August 2015

Google translate

Canine Dilated Cardiomyopathy Drugs Market